Member News
Eyam Vaccines And Immunotherapeutics Embarks On New Licensing Agreement For Creating Innovative Vaccine Technologies
VANCOUVER, BC — Eyam Vaccines and Immunotherapeutics (Eyam), has announced a new licensing agreement for innovative vaccine technologies from the University of British Columbia (UBC), and The James Hutton Institute (JHI). The news comes with the recent development and advancements of new technologies for two novel vaccine vector platforms led by Professor Wilfred Jefferies of Michael Smith Laboratories in Vancouver, Canada, and Dr. Paolo Ribeca at JHI’s Biomathematics and Statistics Scotland in Edinburgh, Scotland.
